CCCC C4 Therapeutics, Inc.

NASDAQ
$2.98

C4 Therapeutics, Inc. (CCCC) is expected to report earnings on November 9, 2026, before the market open. The consensus earnings estimate is a loss of $0.21 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -22.4% since its last earnings release on August 11, 2026.

C4 Therapeutics Beat Consensus Estimates
Tuesday, August 11, 2026 · 7:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 9
Monday · 7:00 AM ET
Earnings Whisper
-
vs ($0.21)
Rev est $9.1M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $3.80

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About C4 Therapeutics, Inc.

C4 Therapeutics Inc. is a biopharmaceutical company. It is focused on harnessing the body's natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. C4 Therapeutics Inc. is based in WATERTOWN, Mass.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.